From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Bupropion is an atypical antidepressant medication sold under the brand names include Wellbutrin, Aplenzin, and Zyban, and formerly Budeprion.[1][2][3] In addition to treating depression and severe pain, it is also used to treat seasonal affective disorder (SAD), and to reduce cravings in smoking cessation and drug addiction.[1][4]

Types[edit | edit source]

Bupropion is available in different forms, and may be combined with other drugs for particular uses, including

  • Bupropion for smoking cessation, brand name Zyban
  • Bupropion for major depression, brand name Wellbutrin[4]

Theory[edit | edit source]

Buproprion, like all antidepressants, does not address the underlying mechanisms of ME/CFS, so should not be regarded as a cure. It should be used only to reduce particular symptoms or treat a co-existing disorder (e.g. depression), and it is not a primary treatment for ME/CFS.[5]

ME/CFS patients may tolerate brand name bupropion better than generic versions due to sensitivities.[citation needed]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "Bupropion: MedlinePlus Drug Information". medlineplus.gov. Retrieved January 8, 2019.
  2. Cite error: Invalid <ref> tag; no text was provided for refs named PMC2729622
  3. Cite error: Invalid <ref> tag; no text was provided for refs named patch
  4. 4.0 4.1 https://www.drugs.com/bupropion
  5. Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02